Home Medicine Serum Lipids and Apolipoproteins in Patients with Psoriasis
Article
Licensed
Unlicensed Requires Authentication

Serum Lipids and Apolipoproteins in Patients with Psoriasis

  • Bekir Sami Uyanik , Zeki Ari , Ece Onur , Kamer Gündüz , Sevcan Tanülkü and Kübra Durkan
Published/Copyright: June 1, 2005
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 40 Issue 1

Abstract

Psoriasis is characterized by defects in the normal cycle of epidermal development that lead to epidermal hyperproliferation, altered maturation of skin cells, vascular changes and inflammation. Also, psoriasis has been associated with an abnormal plasma lipid metabolism. Changes in plasma lipid and lipoprotein composition in patients with psoriasis may be the reason for the increased risk of atherosclerosis in these patients. We determined serum concentrations of lipids, lipoproteins and apolipoprotein A1 and B (apo A1 and apo B) in 72 patients with psoriasis and 30 agematched controls. Serum lipoprotein (a) (Lp(a)), apo A1 and apo B were measured by immunoprecipitation assays, and the lipids and other biochemical parameters by enzymatic methods. Serum Lp(a) and triglyceride (TG) were significantly higher in patients with psoriasis than in healthy control subjects (p<0.01 for both). Apo B was also found to be higher in the patient group, but the difference was not significant. The levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and apo A1 did not differ significantly from those of the controls. These observations imply that serum Lp(a) and TG concentrations may play a role as risk factors for atherosclerotic disease in patients with psoriasis.

:
Published Online: 2005-06-01
Published in Print: 2002-01-29

Copyright © 2002 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. Editorial
  2. Growing Significance of Myeloperoxidase in Non-infectious Diseases
  3. Serum Paraoxonase Activity and the Extent of Lipid Peroxidation Are not Affected by Increased Levels of Human Apolipoprotein A-I: Studies in Transgenic Mice
  4. Relationship between the Sialic Acid Content of Low-Density Lipoprotein (LDL) and Autoantibodies to Oxidized LDL in the Plasma of Healthy Subjects and Patients with Atherosclerosis
  5. The Presence of Heparin-Platelet Factor 4 Antibodies as a Marker of Hypercoagulability during Hemodialysis
  6. Clinical Evaluation of Changes in the Morphology of Eosinophils
  7. The n-3 and n-6 Polyunsaturated Fatty Acid Composition of Plasma Phospholipids in Pregnant Women and Their Infants. Relationship with Maternal Linoleic Acid Intake
  8. Quantification of Sirolimus by Liquid Chromatography-Tandem Mass Spectrometry Using On-Line Solid-Phase Extraction
  9. The Effects of Affinity-Purified Anti-DNA Antibodies Derived from Patients with Systemic Lupus Erythematosus on the Fluorescent Antinuclear Antibody Assay Using HEp-2 Cells
  10. Relationships between Serum Markers of Monocyte/Macrophage Activation in Type 1 Gaucher's Disease
  11. Gender Differences in C-Reactive Protein Concentrations - Confirmation with Two Sensitive Methods
  12. Serum Cholinesterase Activity in Patients with Burns
  13. Serum Lipids and Apolipoproteins in Patients with Psoriasis
  14. Reference Intervals for a Complete Blood Count Determined on different Automated Haematology Analysers: Abx Pentra 120 Retic, Coulter Gen-S, Sysmex SE 9500, Abbott Cell Dyn 4000 and Bayer Advia 120
  15. Science, Alchemy and Light: Paintings by Joseph Wright of Derby
  16. Approved IFCC Reference Method for the Measurement of HbA1c in Human Blood
  17. Meetings and Awards
Downloaded on 30.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2002.013/html
Scroll to top button